Literature DB >> 23500245

Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).

Jacqueline E Tamis-Holland1, Jiang Lu, Mary Korytkowski, Michelle Magee, William J Rogers, Neuza Lopes, Lisa Mighton, Alice K Jacobs.   

Abstract

OBJECTIVES: This study evaluated differences in outcome among women and men enrolled in the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial.
BACKGROUND: Women and men with coronary artery disease have different clinical presentations and outcomes that might be due to differences in management.
METHODS: We compared baseline variables, study interventions, and outcomes between women and men enrolled in the BARI 2D trial and randomized to aggressive medical therapy alone or aggressive medical therapy with prompt revascularization.
RESULTS: At enrollment, women were more likely than men to have angina (67% vs. 58%, p < 0.01) despite less disease on angiography (Myocardial Jeopardy Index 41 ± 24 vs. 46 ± 24, p < 0.01; number of significant lesions 2.3 ± 1.7 vs. 2.8 ± 1.8, p < 0.01). Over 5 years, no sex differences were observed in BARI 2D study outcomes after adjustment for difference in baseline variables (death/myocardial infarction/cerebrovascular accident: hazard ratio: 1.11, 99% confidence interval [CI]: 0.85 to 1.44). However, women reported more angina than men (adjusted odds ratio: 1.51, 99% CI: 1.21 to 1.89, p < 0.0001) and had lower scores for the Duke Activity Status Index (adjusted beta coefficient: -1.58, 99% CI: -2.84 to -0.32, p < 0.01).
CONCLUSIONS: There were no sex differences in death, myocardial infarction, or cerebrovascular accident among patients enrolled in the BARI 2D trial. However, compared with men, women had more symptoms and less anatomic disease at baseline, with persistence of higher angina rates and lower DASI scores after 5 years of medical therapy with or without prompt revascularization. (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D]; NCT00006305).
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23500245     DOI: 10.1016/j.jacc.2013.01.062

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  Sex Differences in Outcomes Following Percutaneous Coronary Intervention According to Age.

Authors:  Kelly C Epps; Elizabeth M Holper; Faith Selzer; Helen A Vlachos; Sarah K Gualano; J Dawn Abbott; Alice K Jacobs; Oscar C Marroquin; Srihari S Naidu; Peter W Groeneveld; Robert L Wilensky
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2016-02

2.  Sex-related differences in self-care behaviors of adults with type 2 diabetes mellitus.

Authors:  Rosario Caruso; Paola Rebora; Michela Luciani; Stefania Di Mauro; Davide Ausili
Journal:  Endocrine       Date:  2020-01-11       Impact factor: 3.633

Review 3.  Acute Coronary Syndromes: Differences in Men and Women.

Authors:  Kris R Kawamoto; Melinda B Davis; Claire S Duvernoy
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 4.  Self-care and type 2 diabetes mellitus (T2DM): a literature review in sex-related differences.

Authors:  Irene Baroni; Rosario Caruso; Federica Dellafiore; Davide Ausili; Serena Barello; Ida Vangone; Sara Russo; Arianna Magon; Gianluca Conte; Luca Guardamagna; Cristina Arrigoni
Journal:  Acta Biomed       Date:  2022-08-31

Review 5.  The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women.

Authors:  LaPrincess C Brewer; Anna Svatikova; Sharon L Mulvagh
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

6.  Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization: Results From the STICH Trial (Surgical Treatment for Ischemic Heart Failure).

Authors:  Ileana L Piña; Qi Zheng; Lilin She; Hanna Szwed; Irene M Lang; Pedro S Farsky; Serenella Castelvecchio; Jolanta Biernat; Alexandros Paraforos; Dragana Kosevic; Liliana E Favaloro; José C Nicolau; Padmini Varadarajan; Eric J Velazquez; Ramdas G Pai; Nicole Cyrille; Kerry L Lee; Patrice Desvigne-Nickens
Journal:  Circulation       Date:  2018-02-20       Impact factor: 29.690

Review 7.  Noninvasive Cardiovascular Risk Assessment of the Asymptomatic Diabetic Patient: The Imaging Council of the American College of Cardiology.

Authors:  Matthew J Budoff; Paolo Raggi; George A Beller; Daniel S Berman; Regina S Druz; Shaista Malik; Vera H Rigolin; Wm Guy Weigold; Prem Soman
Journal:  JACC Cardiovasc Imaging       Date:  2016-02

8.  Outcomes of Participants With Diabetes in the ISCHEMIA Trials.

Authors:  Jonathan D Newman; Rebecca Anthopolos; G B John Mancini; Sripal Bangalore; Harmony R Reynolds; Dennis F Kunichoff; Roxy Senior; Jesus Peteiro; Balram Bhargava; Pallav Garg; Jorge Escobedo; Rolf Doerr; Tomasz Mazurek; Jose Gonzalez-Juanatey; Grzegorz Gajos; Carlo Briguori; Hong Cheng; Andras Vertes; Sandeep Mahajan; Luis A Guzman; Matyas Keltai; Aldo P Maggioni; Gregg W Stone; Jeffrey S Berger; Yves D Rosenberg; William E Boden; Bernard R Chaitman; Jerome L Fleg; Judith S Hochman; David J Maron
Journal:  Circulation       Date:  2021-09-15       Impact factor: 29.690

Review 9.  Sex-Specific Plaque Signature: Uniqueness of Atherosclerosis in Women.

Authors:  Anum Minhas; Ilton Cubero Salazar; Brigitte Kazzi; Allison G Hays; Andrew D Choi; Armin Arbab-Zadeh; Erin D Michos
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 3.955

Review 10.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.